drugset

drugset / Trial / NCT03690544

Apremilast for RAS

NCT03690544 ↗

Phase 4 Completed 15 enrolled Mayo Clinic Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

Determination of treatment efficacy and safety of Apremilast in patients with RAS

Timeline

Start: 2018-10-12
Primary completion: 2021-07-14
Completion: 2021-07-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apremilast	Small molecule	30 mg	Oral

Indications